| Adequate clinical control of congenital nephrotic syndrome by enalapril. | |
| | |
MedLine Citation:
|
PMID: 9543371 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The combination of captopril and indomethacin has been shown to control nephrotic proteinuria in an infant with congenital nephrotic syndrome of the Finnish type. We report the satisfactory control of congenital nephrotic syndrome by enalapril, maintaining normal serum albumin levels without albumin infusions. The haplotype data of our patient were consistent with the diagnosis of a Finnish-type nephrotic syndrome. After 21 months, during which daily infusions of albumin allowed partial control of the symptoms, captopril treatment was started. No adverse effects were noted. Serum creatinine levels remained normal. Within 8 weeks, albumin infusions were completely stopped. After 1 month the treatment was changed to a single dose of enalapril (0.8 mg/kg per day). During the next 15 months, the serum protein concentration was maintained around 6.5-7 g/dl, although proteinuria persisted (0.3-0.5 g/day). Weight and length gain are now satisfactory. We conclude that enalapril may be safely used in infants with severe forms of congenital nephrotic syndrome and might allow the avoidance of aggressive treatments for prolonged periods. |
| | |
Authors:
|
S Guez; M Giani; M L Melzi; C Antignac; B M Assael |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Pediatric nephrology (Berlin, Germany) Volume: 12 ISSN: 0931-041X ISO Abbreviation: Pediatr. Nephrol. Publication Date: 1998 Feb |
Date Detail:
|
Created Date: 1998-06-08 Completed Date: 1998-06-08 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8708728 Medline TA: Pediatr Nephrol Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 130-2 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, University of Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
adverse effects,
therapeutic use* Child, Preschool Enalapril / adverse effects, therapeutic use* Female Finland Follow-Up Studies Haplotypes Humans Molecular Biology Nephrotic Syndrome / congenital*, drug therapy*, genetics Proteinuria / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 75847-73-3/Enalapril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reference values for cystatin C serum concentrations in children.
Next Document: Subclinical activation of lupus nephritis by recombinant human growth hormone.